Analytical Data
-
基因名
EphA2
-
简介
EphA2 protein is a receptor tyrosine kinase that participates in bidirectional signaling with various ephrin A ligands, affecting cell migration, adhesion, proliferation and differentiation. It regulates cell adhesion and differentiation by interacting with DSG1 and inhibiting the ERK1/ERK2 signaling pathway. EphA2 Protein, Human (HEK293, His) is the recombinant human-derived EphA2 protein, expressed by HEK293 , with C-His labeled tag.
- Application
-
生物活性
1. Measured by its binding ability in a functional ELISA. Immobilized rhEphA2 at 2 µg/mL (100 µL/well) can bind rmEphrin-A1. The ED50 for this effect is 4.594-4.847 ng/mL. 2. Measured in a cell proliferation assay using PC-3 cells. The ED50 for this effect is 0.8703 ng/mL, corresponding to a specific activity is 1.15×106 units/mg. Measured in a cell proliferation assay using PC-3 cells.The ED50 for this effect is 0.8703 ng/mL, corresponding to a specific activity is 1.15×106 units/mg.
-
别名
rHuEphrin type-A receptor 2/EphA2, His; Ephrin type-A receptor 2; Epithelial cell kinase; Tyrosine-protein kinase receptor ECK; EPHA2
-
种属
Human
-
表达系统
HEK293
-
标签
C-His
-
纯度
Greater than 95% as determined by SDS-PAGE.
-
蛋白编号
P29317
-
表达区间
A24-N534
-
氨基酸序列
AQGKEVVLLDFAAAGGELGWLTHPYGKGWDLMQNIMNDMPIYMYSVCNVMSGDQDNWLRTNWVYRGEAERIFIELKFTVRDCNSFPGGASSCKETFNLYYAESDLDYGTNFQKRLFTKIDTIAPDEITVSSDFEARHVKLNVEERSVGPLTRKGFYLAFQDIGACVALLSVRVYYKKCPELLQGLAHFPETIAGSDAPSLATVAGTCVDHAVVPPGGEEPRMHCAVDGEWLVPIGQCLCQAGYEKVEDACQACSPGFFKFEASESPCLECPEHTLPSPEGATSCECEEGFFRAPQDPASMPCTRPPSAPHYLTAVGMGAKVELRWTPPQDSGGREDIVYSVTCEQCWPESGECGPCEASVRYSEPPHGLTRTSVTVSDLEPHMNYTFTVEARNGVSGLVTSRSFRTASVSINQTEPPKVRLEGRSTTSLSVSWSIPPPQQSRVWKYEVTYRKKGDSNSYNVRRTEGFSVTLDDLAPDTTYLVQVQALTQEGQGAGSKVHEFQTLSPEGSGN
-
蛋白长度
Extracellular Domain
-
分子量
65-75 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
EphA2 is a receptor tyrosine kinase that plays a crucial role in various biological processes, including cell adhesion, migration, and differentiation. It is predominantly expressed in epithelial cells and has been implicated in several pathological conditions, particularly in cancer progression and metastasis. Abnormal EphA2 expression has been linked to tumor development and poor prognosis in various cancers, making it a potential therapeutic target. The study of EphA2 recombinant proteins is vital for understanding its functional roles and interactions at the molecular level. Researchers aim to develop EphA2-based biomarkers and therapeutic strategies by employing recombinant protein technology, which allows for the production of large quantities of purified protein for functional assays, crystallography, and structural biology studies. Investigating the structure and function of EphA2 can reveal insights into its signaling pathways and may lead to the identification of innovative treatments that inhibit its pro-tumorigenic effects. Additionally, recombinant EphA2 proteins can serve as valuable tools in the development of targeted therapies, including monoclonal antibodies and small molecule inhibitors, further advancing cancer treatment modalities. Thus, research into EphA2 recombinant proteins is critical for both basic and applied sciences, aimed at translating these findings into clinical benefits for patients with EphA2-related diseases.
